Johnson & Johnson is continuing its buying activity in the skin disease space, announcing Tuesday plans to purchase Yellow Jersey Therapeutics, a subsidiary of Numab Therapeutics, and its bispecific antibody NM26 for $1.25 billion in cash.
Japanese conglomerate Asahi Kasei announced Tuesday that it has made a SEK 11.1 billion ($1.1 billion) offer to purchase the Swedish pharmaceutical company Calliditas Therapeutics, with its board of directors recommending that the offer be accepted.
Novartis on Saturday posted two promising Phase III readouts in rare kidney diseases, setting the pharma up for two potential approvals in the space. The company presented these data at the European Renal Association Congress over the weekend.
AstraZeneca and Daiichi Sankyo on Monday revealed additional data from the Phase III TROPION-Lung01 study, showing that their investigational antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) failed to significantly improve overall survival in non-small cell lung cancer patients.
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee on Friday voted against the approval of Novo Nordisk’s once-weekly insulin icodec injection for type 1 diabetes.
Novo Nordisk said it retains about 60% of the list price of its popular diabetes and obesity drugs – Ozempic and Wegovy – after rebates and fees paid to middlemen in the United States, according to a Bloomberg report on Tuesday.